Fault Lines: Business, Reputation, and the Politics Reshaping Pharma

As IRA price negotiations reshape the pharmaceutical landscape, leading policy experts unpack what executives need to know now to navigate pricing uncertainty, biosimilar competition, and long-term strategic risk.

Leavitt Partners' Julie Tierney and RC Resolve, part of Real Chemistry's Maggie Farley, look at which pharma policies could actually pass — and how companies should talk to stakeholders if pricing or manufacturing becomes a flashpoint heading into the midterms.

Skadden's Rachel Turow explains how MFN reference-pricing exposure is changing the way companies sequence global drug launches and what's at stake for patients outside the U.S.

Julie Tierney, Kirsten Axelsen, and Maggie Farley examine how patient advocates, health economists, and communicators are each grappling with MFN's real-world impact.

Kirsten Axelsen unpacks how reshoring trends, tariff exposure, and the Section 301 investigation into Germany's pricing policies are reshaping where pharma manufactures and launches.

Rachel Turow and Maggie Farley examine what's really at stake as companies commit to new U.S. manufacturing — from FDA inspection risk to how these announcements are covered in the press.

Kirsten Axelsen, Julie Tierney, and Rachel Turow discuss what it takes to lead through a pricing environment that will never be the same — and what FDA's new interest in drug pricing really signals.

Rachel Turow and Julie Tierney separate hype from reality on how AI is actually being used in drug development — and inside FDA's own review process.

Kirsten Axelsen, Maggie Farley, Rachel Turow, and Julie Tierney close out this Peer Exchange with the one piece of advice each would give a pharma CEO walking into their next board meeting.